Gentamicin Disk (120MCG)
by Remel, L.P.
510(k) K961818
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK961818 | Date10 Jul 1996 | StatusActive |
Recalls
No FDA recalls found in the data synced 6 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- JTN
- Device Class
- Class II
- Regulation
- 21 CFR Part 866.1620
- Advisory Committee
- Microbiology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 22 Sep 2026
This device is a susceptibility test disc, antimicrobial, used in microbiology for antimicrobial susceptibility testing. It contains gentamicin at a concentration of 120 mcg per disc.
It is supplied as a sterile, single-use disc for in vitro diagnostic use. The device is classified as Class 2 under regulation 866.1620 with product code JTN and received FDA 510(k) clearance K961818 on July 10, 1996, following a traditional review pathway.
Other devices from Remel, L.P.
Questions
AI-generated answers, 22 Sep 2026
What is the Gentamicin Disk 120mcg used for?
This device is an antimicrobial susceptibility test disc used in microbiology laboratories to determine bacterial sensitivity to gentamicin. It contains 120 mcg of gentamicin per disc and is designed for in vitro diagnostic use to support antibiotic selection based on zone of inhibition measurements.
How is the Gentamicin Disk 120mcg supplied and is it sterile?
The disc is supplied as a sterile, single-use product intended for one-time application in susceptibility testing. Sterility ensures no contamination of the test culture, and single-use design prevents cross-contamination between samples, maintaining test accuracy and reliability.
What regulatory pathway was used for the Gentamicin Disk 120mcg?
The device received FDA 510(k) clearance through a traditional review pathway, identified by clearance number K961818, granted on July 10, 1996. This pathway demonstrates substantial equivalence to a legally marketed predicate device, allowing its commercial distribution in the United States.